Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + anlotinib
- Development stage
- Phase 2
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Nivolumab + anlotinib is a combination therapy consisting of two distinct agents used primarily in oncology. Nivolumab is a human IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor to restore anti-tumor immunity by blocking PD-1-mediated signaling. Anlotinib is a small molecule multi-target tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and c-Kit, thereby suppressing tumor angiogenesis and proliferation. The combination has been investigated in clinical trials for advanced solid tumors, including non-small cell lung cancer (NSCLC), gastric adenocarcinoma, esophageal squamous cell carcinoma, soft tissue sarcoma, and small cell lung cancer—especially in patients who have failed standard therapies or are refractory to immune checkpoint inhibitors. Clinical studies report manageable safety profiles and promising efficacy signals with this regimen[2][4][5][6].
- Brand names
- Focus V
- Other names
- nivolumab plus anlotinibanlotinib hydrochloride plus nivolumab
02
Targets
FGFR (FGFR family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on nivolumab + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + anlotinib.